Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.

Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, Binckebanck A, Giagounidis A, Stelljes M, Schmalzing M, Dührsen U, Wunderle L, Serve H, Brück P, Schmidt A, Hoelzer D, Ottmann OG.

Leukemia. 2012 Jul;26(7):1475-81. doi: 10.1038/leu.2012.5. Epub 2012 Jan 9.

PMID:
22230800
2.

Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.

La Rosée P, Holm-Eriksen S, Konig H, Härtel N, Ernst T, Debatin J, Mueller MC, Erben P, Binckebanck A, Wunderle L, Shou Y, Dugan M, Hehlmann R, Ottmann OG, Hochhaus A.

Haematologica. 2008 May;93(5):765-9. doi: 10.3324/haematol.12186. Epub 2008 Mar 26.

3.

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Dührsen U, Schmalzing M, Wunderle L, Binckebanck A, Hoelzer D; GMALL Study Group.

Cancer. 2007 May 15;109(10):2068-76.

4.

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Brück P, Hoelzer D, Ottmann OG.

Blood. 2007 Jul 15;110(2):727-34. Epub 2007 Apr 3.

5.

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhäuser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Brück P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG.

Blood. 2006 Sep 1;108(5):1469-77. Epub 2006 Apr 25.

6.

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Wassmann B, Pfeifer H, Stadler M, Bornhaüser M, Bug G, Scheuring UJ, Brück P, Stelljes M, Schwerdtfeger R, Basara N, Perz J, Bunjes D, Ledderose G, Mahlberg R, Binckebanck A, Gschaidmeier H, Hoelzer D, Ottmann OG.

Blood. 2005 Jul 15;106(2):458-63. Epub 2005 Apr 7.

7.
8.

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Brück P, Binckebanck A, Schleyer E, Gökbuget N, Wolff T, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG.

Clin Cancer Res. 2003 Oct 15;9(13):4674-81.

9.

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.

Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gökbuget N, Atta J, Brück P, Rieder H, Schoch C, Leimer L, Schwerdtfeger R, Ehninger G, Lipp T, Perz J, Stelljes M, Gschaidmeier H, Hoelzer D, Ottmann OG.

Blood. 2004 Feb 15;103(4):1495-8. Epub 2003 Oct 23.

10.

Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

Wassmann B, Scheuring U, Pfeifer H, Binckebanck A, Käbisch A, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG.

Leukemia. 2003 Oct;17(10):1919-24.

PMID:
14513038
11.

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

Wassmann B, Pfeifer H, Scheuring U, Klein SA, Gökbuget N, Binckebanck A, Martin H, Gschaidmeier H, Hoelzer D, Ottmann OG.

Leukemia. 2002 Dec;16(12):2358-65.

Supplemental Content

Loading ...
Support Center